Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N F Hacker

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Translational Oncology|March 26, 2017
Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian CancerC E Henry, C Emmanuel, N Lambie, et al.
British Journal of Cancer|November 26, 2009
Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survivalC A Barton, B S Gloss, W Qu, et al.
Cancer|May 15, 1996
Expression of cell regulatory proteins in ovarian borderline tumorsC van Haaften-Day, P Russell, C M Boyer, et al.
Cancer Treatment Reviews|December 1, 1985
Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancerJ S Berek, N F Hacker, A Lichtenstein, et al.
Cancer Research|March 1, 1983
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvumR C Bast, J S Berek, R Obrist, et al.
Cancer Research|September 1, 1985
Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyJ S Berek, N F Hacker, A Lichtenstein, et al.
American Journal of Obstetrics and Gynecology|August 15, 1985
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvumJ S Berek, R C Knapp, N F Hacker, et al.
Gynecologic Oncology|February 1, 1983
Superficially invasive vulvar cancer with nodal metastasesN F Hacker, R K Nieberg, J S Berek, et al.
Cancer Research|May 1, 1984
Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer modelJ S Berek, J L Cantrell, A K Lichtenstein, et al.
Cancer|December 26, 2001
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisalC van Haaften-Day, Y Shen, F Xu, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Translational Oncology|March 26, 2017
Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian CancerC E Henry, C Emmanuel, N Lambie, et al.
British Journal of Cancer|November 26, 2009
Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survivalC A Barton, B S Gloss, W Qu, et al.
Cancer|May 15, 1996
Expression of cell regulatory proteins in ovarian borderline tumorsC van Haaften-Day, P Russell, C M Boyer, et al.
Cancer Treatment Reviews|December 1, 1985
Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancerJ S Berek, N F Hacker, A Lichtenstein, et al.
Cancer Research|March 1, 1983
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvumR C Bast, J S Berek, R Obrist, et al.
Cancer Research|September 1, 1985
Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyJ S Berek, N F Hacker, A Lichtenstein, et al.
American Journal of Obstetrics and Gynecology|August 15, 1985
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvumJ S Berek, R C Knapp, N F Hacker, et al.
Gynecologic Oncology|February 1, 1983
Superficially invasive vulvar cancer with nodal metastasesN F Hacker, R K Nieberg, J S Berek, et al.
Cancer Research|May 1, 1984
Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer modelJ S Berek, J L Cantrell, A K Lichtenstein, et al.
Cancer|December 26, 2001
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisalC van Haaften-Day, Y Shen, F Xu, et al.
Pageof 13